US EditionEli Lilly stock sinks as pharma misses out on the market rally
- President Donald Trump signed an executive order on May 12 in Washington introducing a 'most-favoured nation' pricing policy for U.S. Prescription drugs.
- The policy aims to reduce drug prices by linking U.S. Costs to the lowest prices paid internationally, with projected reductions between 30% and 80%, though some figures are uncertain.
- The announcement followed a broader market rally driven by a U.S.-China trade deal, but pharmaceutical stocks, including Eli Lilly and Novo Nordisk, declined sharply amid concerns over pricing impacts.
- Shares of Eli Lilly fell 2%, Novo Nordisk dropped 1.9%, while Pfizer was an exception, rising 2.2%, highlighting uneven market reactions within the pharmaceutical sector.
- The order could significantly reduce U.S. Drug prices and profits but faces legal and political challenges, as analysts note potential resistance without new legislation and question its feasibility.
Insights by Ground AI
Does this summary seem wrong?
12 Articles
12 Articles
All
Left
2
Center
1
Right
2
Coverage Details
Total News Sources12
Leaning Left2Leaning Right2Center1Last UpdatedBias Distribution40% Left, 40% Right
Bias Distribution
- 40% of the sources lean Left, 40% of the sources lean Right
40% Right
L 40%
C 20%
R 40%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
